Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
Agentic AI is revolutionizing drug discovery, allowing scientists to generate candidates from simple text prompts and run extended‑reality guided experiments. In parallel, Gilead announced a deal to acquire Tubulis for up to $5 billion, strengthening its antibody‑drug conjugate portfolio. Eli Lilly and Biogen each committed over $6 billion to buy Centessa and Apellis, respectively, expanding their therapeutic footprints. Finally, competition from Novo Nordisk’s Wegovy pill prompted Lilly to lower its 2026 sales forecast for the newly approved oral obesity drug Foundayo.
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
Zeto New Wave EEG System Wins FDA Clearance For At-Home Brain Monitoring
Zeto announced FDA 510(k) clearance for its New Wave EEG system, the company’s third FDA‑approved neuro‑diagnostic platform. The device is a 21‑electrode, gel‑free headset designed for short‑term, up‑to‑2.5‑hour recordings in outpatient clinics and patients’ homes. Integrated with Zeto’s cloud and...
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
A study from Daegu Gyeongbuk Institute of Science and Technology shows that overexpressing the neuropeptide somatostatin (SST) in mice reduces microglial activation, lowers amyloid‑β plaque density, and improves spatial memory in the 5xFAD Alzheimer’s model. In vitro, SST boosted microglial...
China Biotech’s CRISPR Therapy Suggests US Drugmakers Will Face Competition
A Chinese biotech firm used CRISPR‑Cas9 to edit blood stem cells in five beta thalassemia patients, eliminating their need for regular transfusions. The ex‑vivo therapy reactivates fetal hemoglobin and showed durable engraftment with no serious adverse events over a year...
FDA Clears Low-Dose MRI Contrast Agent Vueway for Newborns and Infants
The U.S. Food and Drug Administration has granted an expanded indication for Bracco's Vueway (gadopiclenol) injection, allowing its use in neonates and infants for contrast‑enhanced MRI. The macrocyclic agent delivers high‑quality images at half the standard gadolinium dose (0.05 mmol/kg), addressing...
Using Menstrual Blood-Derived Particles to Treat Osteoarthritis
Lithuanian researchers have demonstrated that extracellular vesicles (EVs) harvested from menstrual‑blood‑derived mesenchymal stromal cells can stimulate cartilage regeneration in vitro, offering a cell‑free therapy for osteoarthritis. The EVs improved chondrocyte function and extracellular matrix synthesis even in cartilage cells taken...
Blackstone’s Galakatos on Scaling Deals with $6.3B Fund: ‘Broader, Further’
Blackstone’s Galakatos team announced a new $6.3 billion private‑equity fund aimed at scaling the number and size of its transactions. The fund will pursue a broader geographic footprint and deeper sector coverage, focusing on later‑stage growth and buy‑and‑build opportunities. Galakatos plans...
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics, a Shanghai‑based biotech, closed a pre‑IPO financing round of more than $110 million to accelerate its CAR‑T programs targeting solid tumors, starting with liver cancer. Its lead candidate, Ori‑C101, targets the GPC3 protein and has shown a 60% response...
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
Vivatides Therapeutics announced a $54 million Series A round to accelerate its pre‑clinical siRNA and antisense oligonucleotide programs, with Sequoia Capital leading the investment. In Europe, Novo Nordisk confirmed that its obesity drug Wegovy will drop the costly cold‑chain requirement, simplifying distribution. Meanwhile,...
Shooting People In The Head and Heart with mRNA Vaccines, Murder One or Insanity?
A recent blog post dramatizes a WHO‑backed Global Vaccine Data Network (GVDN) study that examined 99 million vaccine recipients across eight countries. The study confirmed strong myocarditis and pericarditis signals after mRNA COVID‑19 vaccines, while Guillain‑Barré syndrome and cerebral venous sinus...
FDA/Center for Research on Complex Generics (CRCG) Workshop on Bioequivalence Innovations for Generic Oral Products: Biowaivers, Bridging, and Development for...
On May 5‑6, 2026, the FDA’s Center for Research on Complex Generics hosted a two‑day workshop in Rockville, MD to explore innovative bioequivalence (BE) strategies for generic oral drugs. The agenda covered biowaivers, bridging studies, and development pathways for oncology agents,...
Biotech VCs Ramp up Checks on New Bets After Years of Focusing on Existing Portfolios
Biotech venture capitalists are shifting back to high‑risk, high‑reward investing, with 65% of Q1 2026 capital directed at new startups. Total venture funding in the sector rose to roughly $2.1 billion, up from $1.5 billion a quarter earlier, and average deal size climbed...
Can Forgotten Biotech Break Out?
The iShares Biotechnology ETF (IBB) surged more than 50% from its April lows to a mid‑January peak, then entered a prolonged sideways phase. Recent price action shows the fund just reclaimed its 50‑day moving average but has yet to breach...
How to Master the Pharmacovigilance System Master File for Inspection Readiness
Mastering the Pharmacovigilance System Master File (PSMF) is essential for inspection readiness, as regulators use it to gauge a company’s PV compliance before any formal interview. In the EU and UK, the PSMF must be supplied within seven days of...
An Implantable Living Pharmacy Produces Drugs in the Body
Scientists from Northwestern, Rice, and Carnegie Mellon unveiled a sub‑cutaneous implant called HOBIT that can synthesize multiple biologic drugs inside the body. The device houses engineered cells in an alginate hydrogel and an electrocatalytic oxygenator that supplies oxygen, enabling sustained...
What’s in a Name? Moderna’s “Vaccine” Vs. “Therapy” Dilemma
Moderna has stopped calling its mRNA melanoma product a "vaccine," rebranding it as an individualized neoantigen therapy (INT) to sidestep growing political resistance to vaccines. The shift follows the cancellation of a $776 million federal bird‑flu vaccine contract and broader skepticism...
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (Avutometinib Capsules; Defactinib Tablets) in Recurrent Low-Grade Serous...
Verastem Oncology presented two‑year median follow‑up data from its Phase 2 RAMP 201 trial of the AVMAPKI® FAKZYNJA® combination (avutometinib + defactinib) in recurrent low‑grade serous ovarian cancer (LGSOC). The updated analysis confirmed a median duration of response of 31.1 months and a median progression‑free survival...
A Common Nutrient Could Supercharge Cancer Treatment
University of Chicago researchers found that the dietary carotenoid zeaxanthin directly boosts CD8⁺ T‑cell activity, enhancing the immune system's ability to recognize and destroy cancer cells. In mouse models, dietary zeaxanthin slowed tumor growth and amplified the effects of checkpoint‑inhibitor...
Personalized CRISPR Fixes Baby KJ’s Genetic Defect
In just 6 months a team at @ChildrensPhila & @PennMedicine designed a personalized CRISPR based Rx to correct the single misspelled letter in Baby KJ’s DNA that results in CPS1 deficiency. Recent advances in mRNA science & CRISPR gene...
Vutrisiran Cuts Risk of Advanced ATTR-CM, Improves Outcomes in Those Who Progress
Vutrisiran (Amvuttra) demonstrated in the phase 3 HELIOS‑B trial that it slows progression to advanced heart failure in transthyretin amyloid cardiomyopathy (ATTR‑CM), with 8.0% of treated patients reaching advanced disease versus 10.7% on placebo. Among the 61 patients who did progress,...
Opinion: For AI to Have Impact, the Industry Must Align on Data
Artificial intelligence is now embedded across biopharmaceutical R&D, highlighted by the FDA's adoption of the generative tool Elsa for drug‑approval reviews. Industry leaders, including Charles River Laboratories, warn that AI's promise hinges on the quality, metadata, and harmonization of the...
EU Launches PsyPal Trial to Test Psychedelic Therapy for Palliative Care Distress
The European Union has kicked off the PsyPal project, a clinical trial that will evaluate psychedelic‑assisted therapy for psychological distress among palliative‑care patients. The trial launched on 13 April 2026 at the Directorate‑General for Health and Food Safety, signaling a new research...
Ancient Asgard Archaeon Discovered in Shark Bay Illuminates Origin of Complex Life
An international research team has isolated a living Asgard archaeon from the stromatolite mats of Shark Bay, Western Australia, and captured its direct nanotube connection to a sulfate‑reducing bacterium. The finding offers the first visual evidence of the symbiotic partnership...
Wyss Institute’s Organ‑Chip Avatars Fly on Artemis II to Probe Astronaut Health
The Wyss Institute for Biologically Inspired Engineering and Emulate, Inc. have placed human bone‑marrow organ‑chip “avatars” on NASA’s Artemis II mission, launched April 1, 2026, to study how radiation and microgravity affect astronaut tissue. The experiment could reshape space‑medicine research and give...
Revvity Unveils Its Signals BioDesign Offering
Revvity Signals Software introduced Signals BioDesign, a cloud‑native molecular cloning platform aimed at biotech and pharma R&D teams. The solution consolidates Golden Gate, Gibson assembly, restriction/ligation, primer design, and sequencing analysis, supporting up to 1,000 constructs per project. Integrated with...
Oricell Therapeutics Secures $110 Million Pre‑IPO Funding, Spotlighting Investment Banking Activity
Oricell Therapeutics closed a pre‑IPO financing round exceeding $110 million, co‑led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund and Qiming Venture Partners. The capital will fund global expansion and pivotal trials for its lead CAR‑T candidate, while...
Exploring the Value of Quality Peptide Supplies
Peptide research has surged, making high‑purity synthetic peptides essential for reliable experiments. Quality hinges on ≥98% purity verified by HPLC, accurate molecular weight confirmed by mass spectrometry, and proper lyophilization with cold‑chain logistics. The article outlines a supplier checklist—third‑party testing,...
Chinese Researchers Demonstrate CRISPR Cure for Β‑Thalassaemia in Clinical Trial
A consortium of Chinese scientists has shown that an enhanced CRISPR/Cas9 platform can safely correct the genetic defect behind β‑Thalassaemia in patients. The study builds on the recent FDA approval of a CRISPR therapy for sickle‑cell anemia and suggests a...
Top Biotech Deals in March 2026
Biotech M&A activity peaked in March 2026 with twelve announced deals, eight of which were multi‑billion‑dollar transactions. The largest was Lilly’s $7.8 billion acquisition of Centessa, adding an orexin‑receptor‑2 program for narcolepsy. Other marquee deals included Biogen’s $5.6 billion purchase of Apellis, Merck’s...
Senju Launches First-in-Class Dry Eye Disease Drug in Japan
Senju Pharma has launched Avarept, the first TRPV1 antagonist drug for dry eye disease (DED) in Japan, licensed from Mochida and distributed by Takeda. The ophthalmic suspension is priced at ¥577.50 (approximately $3.63) per 5 ml bottle. DED affects over 20 million...
NVIDIA Just Helped Map 31 Million Protein Complexes and the Health Tech Investment Implications Are Enormous
NVIDIA, DeepMind, EMBL‑EBI and Seoul National University expanded the AlphaFold Protein Structure Database to include 31 million predicted protein complexes—23.4 million homodimers and 7.6 million heterodimers—across 4,777 proteomes. Using H100 DGX Superpod clusters, MMseqs2‑GPU and TensorRT‑accelerated inference, the team generated 1.8 million high‑confidence homodimer...
Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-Cell Engagers for Solid Tumors
Oxford BioTherapeutics (OBT) announced a multi‑year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next‑generation T‑cell engager therapies for solid tumors. OBT will apply its OGAP‑Verify platform to identify tumor‑selective antigens and design candidate molecules, while BMS...
Oricell Therapeutics Raises $110 Million to Advance Global Cell Therapy Development
Oricell Therapeutics announced a $110 million pre‑IPO financing round aimed at accelerating its global cell‑therapy program. The capital will fund expanded clinical trials, manufacturing upgrades, and a broader market rollout, especially for its lead liver‑cancer therapy that is nearing pivotal studies....
NMN Daily Restores NAD, Supports Healthy Aging
David Sinclair takes 1 gram of NMN every single day. Here's why. As you age, your body loses up to 50% of a molecule called NAD. NAD is a molecule that acts like fuel powering your sirtuin genes - the genes responsible...
Young Mitochondria Transplants Could Reverse Aging and Disease
What if aging, ALS, Parkinson's, stroke, and diabetes all share a single upstream cause — and the fix is a transplant the size of a bacterium? Dr. Catherine Baucom and Van Hipp of MitoSense explain how injecting healthy young mitochondria...
Endospan Receives FDA Approval for the NEXUS Aortic Arch Stent Graft System
Endospan announced FDA approval of its NEXUS Aortic Arch Stent Graft System, clearing the way for a U.S. commercial launch. The clearance was based on one‑year results from the TRIOMPHE IDE study, which demonstrated safe and effective treatment of high‑risk...
Will RFK Jr.’s Peptide Push Bolster the Gray Market for Obesity Drugs?
Robert F. Kennedy Jr. is urging the FDA to reclassify more than a dozen synthetic peptides from the restricted Category 2 list to Category 1, allowing compounding by licensed pharmacies with a prescription. The move follows a high‑profile appearance on the Joe...
Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma
Biotech IPO activity is resurging, highlighted by Evommune’s public listing and a panel at the BIO International Convention discussing renewed exit opportunities. AI-driven collaborations, such as Insilico Medicine and Aska Pharmaceutical, aim to tackle unmet needs in women’s health by...
InVera Medical Receives FDA Clearance for Non-Thermal Chronic Venous Disease Device
InVera Medical secured FDA 510(k) clearance for its InVera Infusion Device, a 5Fr catheter with a helical coil designed to improve sclerotherapy delivery for chronic venous disease (CVD). The non‑thermal, minimally invasive tool prepares the vein wall mechanically, allowing a...
Diagnostics Lag Is Holding Back New Therapies, Says Study
A new UCSF analysis published in Science warns that diagnostic development is lagging behind therapeutic breakthroughs because of regulatory and reimbursement gaps. The authors highlight that nearly half of the world’s population—about 47%—has limited or no access to essential tests,...
Blocking 15-PGDH Reverses Age‑Related Cartilage Loss
As a medical school professor, I was taught that lost cartilage is gone forever. Stanford just proved that wrong. Researchers discovered that blocking a single protein (15-PGDH) -- which rises as we age -- can actually REGROW joint cartilage in aging mice. The...
Replimune's FDA‑targeted Skin Cancer Drug Faces Another Rejection
Replimune $REPL skin cancer drug that became FDA flashpoint is rejected again https://t.co/7aOfKy8vC7 via @Jasonmmast
DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer
DualityBio announced that China’s National Medical Products Administration has accepted its Biologics License Application for trastuzumab pamirtecan (T‑Pam), an investigational antibody‑drug conjugate targeting HER2‑positive metastatic breast cancer. The submission is backed by interim data from the pivotal Phase III DB‑1303‑O‑3001 trial,...
Psychedelic Therapies May Outpace GLP‑1s Commercially
I believe the commercial potential of #psychedelic therapies is likely to exceed that of GLP-1s. $ATAI $CMPS $DFTX
Optical Genome Mapping Enhances AML Classification and Treatment
Optical genome mapping [OGM] improves the accuracy of classification, risk stratification, & personalized treatment strategies for Pts w/ acute myeloid leukemia [Jul 17, 2024] @sanamloghavi et al. @AjHematology https://t.co/R5ZLgolhuj #AMLsm #leusm #PrecisionMedicine #oncopath https://t.co/kX7KUJLK0L
Sex Drives Distinct Immune Aging Patterns and Disease Risks
The way our immune cells age differs substantially by sex, from single-cell analysis of ~1,000 people. Implications for propensity for autoimmune diseases (women), vulnerability to cancer (men), immunosenescence and inflammaging @NatureAging https://t.co/GjcuZ8luNM
Biotech IPO Surge Expected; List on NYSE
Getting to know the @NYSE and Johanna and Eric has been a highlight of mine since their earliest support of BiotechTV. I have no doubt we will see a strong IPO pipeline for biotech this year, and I hope you...
Ultrasound Enables Non‑Invasive Control of Body Cells
"Sonogenics" is an emerging scientific field that uses ultrasound to non-invasively control and manipulate specific cells in the body, such as neurons or heart cells
Regeneration Depends on Environment, Oxygen, and Epigenetics
Awakening latent regeneration in mammals “regeneration is not simply a fixed genetic trait but rather a state that is dependent on the extracellular environment, oxygen sensing, and epigenetics.” https://t.co/HtTXENUEur